PPIDT00075

Drug Information
NameAlefacept
SequenceCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00092
Typebiotech
IndicationAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis

Dosage Forms
Form Route Strength
Kit Intramuscular
15 mg/0.5mL
Powder, for solution Intramuscular
15 mg / 0.5 mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P06729 CD2 T-cell surface antigen CD2 Homo sapiens inhibitor|antibody|regulator Link
target P08637 FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A Homo sapiens unknown Link
target O75015 FCGR3B Low affinity immunoglobulin gamma Fc region receptor III-B Homo sapiens unknown Link